Table 1.
Patient baseline characteristics (N = 79).
| Variable | Value | |
|---|---|---|
| Age at transplant, median in years (IQR) | 38 | (27–47) |
| Interval between diagnosis and transplant, median in days (IQR) | 696 | (209–753) |
| Diagnosis n (%) | ||
| AML | 54 | (68.4) |
| ALL | 25 | (31.6) |
| Disease stage, n (%) | ||
| CR1 | 37 | (46.9) |
| CR2 | 20 | (25.3) |
| Advanced* | 22 | (27.8) |
| Recipient Sex, n (%) | ||
| Male | 44 | (55.7) |
| Female | 35 | (44.3) |
| Donor Type, n (%) | ||
| Related | 61 | (77.2) |
| Unrelated | 18 | (22.8) |
| Conditioning regimen, n (%) | ||
| MAC | 73 | (92.4) |
| RIC | 6 | (7.6) |
| Stem cell source, n (%) | ||
| Bone marrow | 17 | (21.5) |
| Peripheral blood | 62 | (78.5) |
| CMV serostatus (recipient), n (%) | ||
| Positive | 70 | (88.6) |
| Negative | 9 | (11.4) |
| CMV serostatus (donor), n (%) | ||
| Positive | 63 | (79.7) |
| Negative | 12 | (15.2) |
| Unknown | 4 | (5.1) |
| Donor-recipient serostatus combination, n (%) | ||
| Both negative | 3 | (3.8) |
| Both positive | 57 | (72.1) |
| Positive/Negative | 6 | (7.6) |
| Negative/Positive | 9 | (11.4) |
| Unknown/Positive | 4 | (5.1) |
| Karnofsky performance status, n (%) | ||
| ≥ 80% | 76 | (96.2) |
| < 80% | 3 | (3.8) |
| AL-EBMT score, n (%) | ||
| Low | 32 | (40.5) |
| Intermediate | 10 | (12.7) |
| High | 37 | (46.8) |
AL-EBMT score: acute leukemia – European society for blood and marrow transplantation score; CMV: cytomegalovirus; IQR: interquartile range; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; MAC: myeloablative conditioning (regimen); RIC: reduced intensity conditioning (regimen); CR1: first complete remission; CR2: second complete remission.
⁎
Advanced = refractory disease and > CR2.